Still, under any scenario, "the overall pace of many of the programs could be impacted as the investigation progresses and the sponsors become more vigilant," the analyst wrote. But in an indication AstraZeneca may have the issue under control, the Financial Times reported on Wednesday the trial could resume next week, citing people familiar with the matter. RELATED: AstraZeneca's COVID-19 vaccine hold sparks reassessment of race Meanwhile, SVB Leerink's Mani Foroohar, who on Tuesday downgraded AZ rival Moderna due to competitive pressures, said the mRNA biotech's share price should react favorably to the news.